ALAS2 and X-linked lymphoproliferative disease: Previously, we demonstrated that purified recombinant human ALAS2 enzymes from XLP patients with mutations in the gain-of-function region led to 1.6- to 3.1-fold increased enzymatic specific activity (Bishop et al. 2013).